Stockscreener 앱 받기
4.845
1.79%
0.085
전일 마감가:
$4.76
열려 있는:
$4.71
하루 거래량:
18,268
Relative Volume:
0.12
시가총액:
$284.18M
수익:
$30.91M
순이익/손실:
$-74.28M
주가수익비율:
-3.9769
EPS:
-1.2183
순현금흐름:
$-86.15M
1주 성능:
-7.01%
1개월 성능:
-1.72%
6개월 성능:
+37.25%
1년 성능:
+14.27%
1일 변동 폭
$4.71
$4.87
1주일 범위
$4.63
$5.36
52주 변동 폭
$3.27
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.84 | 279.48M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
427.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.12 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.74 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.51 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 재개 | Jefferies | Buy |
| 2025-12-18 | 개시 | BTIG Research | Buy |
| 2025-11-07 | 개시 | Guggenheim | Buy |
| 2025-09-17 | 재개 | B. Riley Securities | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
[ARS] Foghorn Therapeutics Inc. SEC Filing - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9%Time to Sell? - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating on AACR data - Investing.com
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Should I sell Foghorn Therapeutics (FHTX) stock today | Q4 2025: Earnings UnderperformExpert Momentum Signals - Xã Châu Thành
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn presents preclinical data for cancer drug candidates By Investing.com - Investing.com South Africa
FHTX Unveils Promising Preclinical Data at AACR Annual Meeting - GuruFocus
Foghorn presents preclinical data for cancer drug candidates - Investing.com
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR - TipRanks
Foghorn Therapeutics presents new preclinical data on SMARCA2 inhibitor FHD-909 and targeted degrader programs - Traders Union
Foghorn Therapeutics Presents New Preclinical Data for - GlobeNewswire
Foghorn Therapeutics (Nasdaq: FHTX) showcases broad preclinical cancer data and cash runway outlook - Stock Titan
Foghorn Therapeutics (FHTX) Stock: Short-Term vs Long-Term (Eye on Rally) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Foghorn (NASDAQ: FHTX) CEO shifts 213,410 shares in trust-to-trust gifts - Stock Titan
If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan
Trading Recap: Can Foghorn Therapeutics Inc weather a recession2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Investing News Network
Foghorn to present preclinical cancer data at AACR meeting By Investing.com - Investing.com South Africa
Foghorn Therapeutics details preclinical advances across oncology programs - Traders Union
Foghorn to present preclinical cancer data at AACR meeting - Investing.com
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor ... - Bluefield Daily Telegraph
Foghorn Therapeutics to Present New Preclinical Data for - GlobeNewswire
FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FHTX Technical Analysis & Stock Price Forecast - Intellectia AI
FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada
FHTX Should I Buy - Intellectia AI
Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn
Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
2.04%
자본화:
|
볼륨(24시간):